Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
| Previous Close | 1.3300 |
| Open | 1.3000 |
| Bid | 1.3400 x 43500 |
| Ask | 1.3500 x 39400 |
| Day's Range | 1.2800 - 1.3700 |
| 52 Week Range | 1.1200 - 2.5450 |
| Volume | |
| Avg. Volume | 18,638,704 |
| Market Cap | 2.881B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Agrivalle and Ginkgo Bioworks Enter Multiyear Strategic Partnership to Accelerate Next-Gen Ag Biological Products
Agrivalle, a leading Brazilian agricultural biologicals company, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Together, the companies will collaborate on building cutting edge technologies to advance Agrivalle's biological products, including next-gen fertilizers and biocontrol agents.
- PR Newswire
Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan
Synplogen Co., a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding ("MOU"). Together, Synplogen and Ginkgo intend to accelerate the global development of DNA manufacturing
- PR Newswire
Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins
Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive capabilities in strain engineering, optimization and performance, to develop and commercialize a next generation of functional alternative protein.
